Prosecution Insights
Last updated: November 04, 2026
Application No. 18/910,152

(2,5-DIOXOPYRROLIDIN-1-YL)(PHENYL)-ACETAMIDE DERIVATIVES AND THEIR USE IN THE TREATMENT OF NEUROLOGICAL DISEASES

Non-Final OA §101§112
Filed
Oct 09, 2024
Priority
Jan 07, 2019 — PL P.428485 +2 more
Examiner
AULAKH, CHARANJIT
Art Unit
1621
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Warszawski Uniwersytet Medyczny
OA Round
1 (Non-Final)
81%
Grant Probability
Favorable
1-2
OA Rounds
0m
Est. Remaining
66%
With Interview

Examiner Intelligence

Grants 81% — above average
81%
Career Allowance Rate
1448 granted / 1794 resolved
+20.7% vs TC avg
Minimal -14% lift
Without
With
+-14.5%
Interview Lift
resolved cases with interview
Fast prosecutor
2y 0m
Avg Prosecution
53 currently pending
Career history
1840
Total Applications
across all art units

Statute-Specific Performance

§101
3.4%
-36.6% vs TC avg
§103
14.8%
-25.2% vs TC avg
§102
20.5%
-19.5% vs TC avg
§112
43.6%
+3.6% vs TC avg
Black line = Tech Center average estimate • Based on career data from 1794 resolved cases

Office Action

§101 §112
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Claims 1-10 and 12-14 are pending in the application. There is no claim 11 in the application. Claim Objections Claims 3-10 and 12-14 are objected to under 37 CFR 1.75(c) as being in improper form because a multiple dependent claim should refer to other claims in alternate only. See MPEP § 608.01(n). Claim Rejections - 35 USC § 112 4. The following is a quotation of 35 U.S.C. 112(b): (b) CONCLUSION.—The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the inventor or a joint inventor regards as the invention. The following is a quotation of 35 U.S.C. 112 (pre-AIA ), second paragraph: The specification shall conclude with one or more claims particularly pointing out and distinctly claiming the subject matter which the applicant regards as his invention. Claims 1-10 and 12-14 are rejected under 35 U.S.C. 112(b) or 35 U.S.C. 112 (pre-AIA ), second paragraph, as being indefinite for failing to particularly point out and distinctly claim the subject matter which the inventor or a joint inventor (or for applications subject to pre-AIA 35 U.S.C. 112, the applicant), regards as the In invention. In claims 2-10 and 12-13, the term - - - characterized in that - - - is vague. The applicants are suggested to use the term - - wherein - - -. Claim 14 is directed to use of the compounds of claims 1-13 for treating but not preventing diseases. However, it is not clear who is being treated? and furthermore, the steps of administration are also missing in the claim. A broad range or limitation together with a narrow range or limitation that falls within the broad range or limitation (in the same claim) may be considered indefinite if the resulting claim does not clearly set forth the metes and bounds of the patent protection desired. See MPEP § 2173.05(c). In the present instance, independent claim 1 as well as claim 2 recites the broad recitation benzothiophenyl substituent for variable A, and the claim also recites preferably 5-benzothiophenyl substituent which is the narrower statement of the range/limitation. Independent claim 1 as well as claim 2 recites the broad recitation benzisoxazole substituent for variable A, and the claim also recites preferably 5-benzisoxazole substituent which is the narrower statement of the range/limitation. Independent claim 1 as well as claim 2 recites the broad recitation an alkyl moiety for variable B, and the claim also recites preferably alkyl moiety substituted with atleast one halogen which is the narrower statement of the range/limitation. Independent claim 1 recites the broad recitation amino group substituted with one or two aliphatic substituents for variable D, and the claim also recites including in particular CH3 and/or C2H5 which is the narrower statement of the range/limitation. The claim(s) are considered indefinite because there is a question or doubt as to whether the feature introduced by such narrower language is (a) merely exemplary of the remainder of the claim, and therefore not required, or (b) a required feature of the claims. Double Patenting A rejection based on double patenting of the “same invention” type finds its support in the language of 35 U.S.C. 101 which states that “whoever invents or discovers any new and useful process... may obtain a patent therefor...” (Emphasis added). Thus, the term “same invention,” in this context, means an invention drawn to identical subject matter. See Miller v. Eagle Mfg. Co., 151 U.S. 186 (1894); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Ockert, 245 F.2d 467, 114 USPQ 330 (CCPA 1957). A statutory type (35 U.S.C. 101) double patenting rejection can be overcome by canceling or amending the claims that are directed to the same invention so they are no longer coextensive in scope. The filing of a terminal disclaimer cannot overcome a double patenting rejection based upon 35 U.S.C. 101. Claims 1-10 and 12-14 are rejected under 35 U.S.C. 101 as claiming the same invention as that of claims 1-10 and 13-18 of prior U.S. Patent No. 12,139,458, cited on applicant’s form 1449. This is a statutory double patenting rejection. Allowable Subject Matter The following is a statement of reasons for the indication of allowable subject matter: The instant compounds of formula (I) are allowable over the prior art since they are neither disclosed nor obvious over the prior art. In the prior art, Abram (J. Med. Chem., cited on applicant’s form 1449) discloses compounds 19-34 and 37-41 (see scheme 1 on page 8567) which are closely related to the instant compounds when variable X represents N in the instant compounds. However, the compounds of Abram differ from the instant compounds by having value of instant variable B as hydroxy or alkoxy instead of instant phenyl group. Furthermore, there is no teaching, suggestion or motivation in the prior art to modify the compounds of Abram to prepare instant compounds. Any inquiry concerning this communication or earlier communications from the examiner should be directed to CHARANJIT AULAKH whose telephone number is (571)272-0678. The examiner can normally be reached Monday-Friday 7:00-3:30. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Clinton A Brooks can be reached at 571-270-7682. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /CHARANJIT AULAKH/ Primary Examiner, Art Unit 1621
Read full office action

Prosecution Timeline

Oct 09, 2024
Application Filed
Oct 22, 2026
Non-Final Rejection mailed — §101, §112 (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12780820
3-(1H-IMIDAZOL-2-YL)-2,3,8,8A-TETRAHYDROINDOLIZIN-5(1H)-ONE DERIVATIVES USEFUL AS FACTOR XIA INHIBITORS
3y 9m to grant Granted Nov 03, 2026
Patent 12780843
A SYNTHESIS OF COPPER (I) 5-NITROTETRAZOLATE
3y 1m to grant Granted Nov 03, 2026
Patent 12778958
Managing the Acute and Long-Term Effects of Coronaviral Infections and Compositions Related Thereto
3y 1m to grant Granted Nov 03, 2026
Patent 12787633
TETRADENTATE PLATINUM AND PALLADIUM COMPLEXES BASED ON BISCARBAZOLE AND ANALOGUES
2y 6m to grant Granted Nov 03, 2026
Patent 12777771
ORGANIC COMPOUND AND SENSOR AND SENSOR EMBEDDED DISPLAY PANEL AND ELECTRONIC DEVICE
3y 11m to grant Granted Oct 27, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
81%
Grant Probability
66%
With Interview (-14.5%)
2y 0m (~0m remaining)
Median Time to Grant
Low
PTA Risk
Based on 1794 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month